Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for chinese men with tough prostate cancer: targeted drug takes on standard care

NCT ID NCT05457257

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares the targeted drug olaparib to two standard hormone therapies (enzalutamide or abiraterone) in Chinese men with advanced prostate cancer that has stopped responding to hormone treatment and who have BRCA1/2 gene mutations. The goal is to see if olaparib can delay cancer growth better than the usual options. About 43 men will participate, and the study tracks how long their cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

43 people

The number who actually took part.

Started

Jul 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria： 1. Histologically confirmed diagnosis of prostate cancer. 2. Documented evidence of metastatic castration resistant prostate cancer (mCRPC). 3. Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and/or enzalutamide) for the treatment of metastatic prostate cancer and/or CRPC . 4. Ongoing therapy with LHRH analog or bilateral orchiectomy. 5. Radiological progression at study entry while on androgen deprivation therapy (or after bilateral orchiectomy). 6. Deleterious or suspected deleterious BRCA1/2 mutation in tumor tissue. 7. Normal organ and bone marrow function measured within 28 days prior to administration of study treatment. 8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing. Exclusion criteria： 1. Any previous treatment with a poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor, including olaparib. 2. Subjects who had any previous treatment with DNA-damaging cytotoxic chemotherapy, except if for non-prostate cancer indication and last dose \> 5 years prior to randomization. 3. History of another primary malignancy except for malignancy treated with curative intent with no known active disease for ≥5 years before the first dose of study intervention and of low potential risk for recurrence. 4. Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic castration resistant prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic castration resistant prostate cancer

Contacts and locations

Locations

  • Research Site

    Beijing, 100050, China

  • Research Site

    Bengbu, 233004, China

  • Research Site

    Changsha, 410008, China

  • Research Site

    Changsha, 410013, China

  • Research Site

    Chengdu, 610000, China

  • Research Site

    Chongqing, 408099, China

  • Research Site

    Fuzhou, 350005, China

  • Research Site

    Guangzhou, 510060, China

  • Research Site

    Guangzhou, 510180, China

  • Research Site

    Hangzhou, 310003, China

  • Research Site

    Hangzhou, 310009, China

  • Research Site

    Hangzhou, 310014, China

  • Research Site

    Hefei, 230601, China

  • Research Site

    Jiaxing, 314001, China

  • Research Site

    Jinan, 250012, China

  • Research Site

    Jinan, 250021, China

  • Research Site

    Jining, 272029, China

  • Research Site

    Kunming, 650101, China

  • Research Site

    Lanzhou, 730030, China

  • Research Site

    Linyi, 276000, China

  • Research Site

    Nanchang, 330006, China

  • Research Site

    Nantong, 226361, China

  • Research Site

    Ningbo, 315010, China

  • Research Site

    Shanghai, 200002, China

  • Research Site

    Shanghai, 200032, China

  • Research Site

    Shenyang, 110004, China

  • Research Site

    Suzhou, 215004, China

  • Research Site

    Taiyuan, 030000, China

  • Research Site

    Tianjin, 300060, China

  • Research Site

    Wanzhou, 404000, China

  • Research Site

    Wuhan, 430022, China

  • Research Site

    Wuxi, 214002, China

  • Research Site

    Wuxi, 214023, China

  • Research Site

    Xi'an, 710077, China

  • Research Site

    Zhengzhou, 450052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.